The top pre-market NASDAQ stock market gainers are: Cytori Therapeutics, Spectrum Pharmaceuticals, Zix, Powerwave Technologies, optionsXpress Holdings, Interactive Brokers Group, Qiao Xing Universal Resources, Seagate Technology, and Fifth Third Bancorp.

Cytori Therapeutics, Inc. (CYTX) climbed 14.81 percent to $5.97 in the pre-market trading. The company said it entered into a strategic equity deal with Astellas Pharma Inc. to evaluate the potential of adipose derived stem and regenerative cells to treat serious illnesses for which there is no fundamental treatment.

Cytori Therapeutics to sell nearly its 1.43 million unregistered common shares at $7.00 a share for net proceeds of $10 million to Astellas Pharma. The transaction is expected to close around Dec. 13.

Spectrum Pharmaceuticals, Inc. (SPPI) surged 9.24 percent to $5.91 in the pre-market session. The company said its ZEVALIN drug showed positive results in the first phase 2 clinical trail to treat patients with a type of cancer called follicular non-Hodgkin's lymphoma

Spectrum said the drug achieved a one-year overall complete response rate of 53 percent in the first Phase 2 clinical trial evaluating ZEVALIN injection for intravenous use as a monotherapy. The response rate was similar to rates reported in previous trials evaluating standard chemotherapy alone, or chemotherapy followed by ZEVALIN, in non-Hodgkin's lymphoma.

Zix Corp. (ZIXI) improved 4.11 percent to $4.05 in the pre-market trading.

Powerwave Technologies Inc. (PWAV) soared 4.08 percent to $2.55 in the pre-market trading.

optionsXpress Holdings, Inc. (OXPS) jumped 3.19 percent to $20.71 in the pre-market session. The stock has reached its 2-year high of $20.46 during Monday's regular trading.

Interactive Brokers Group, Inc. (IBKR) gained 3.12 percent to $17.87 in the pre-market session.

Qiao Xing Universal Resources, Inc. (XING) grew 2.99 percent to $2.07 in the pre-market trading.

Seagate Technology PLC (STX) rose 2.83 percent to $15.27 in the pre-market trading.

Fifth Third Bancorp (FITB) increased 2.53 percent to $13.35 in the pre-market trading.

NASDAQ Stock Market Cancer Lymphoma Medicine